Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMCOMG: Immediate Corticosteroids and Rituximab in Ocular Myasthenia
NCT06342544Phase 3Recruiting
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Apr 2025
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab, prednisone in myasthenia gravis (MG), sponsored by Adolphe de Rothschild Foundation Hospital. Started Apr 2025; status: recruiting.
02
Drugs
rituximabprednisone
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06342544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06342544.